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Background: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic
colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard
capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in previously untreated patients with mCRC.
Methods: Patients received intravenous irinotecan 175 mg/m2 on day 1 and oral capecitabine 1000 mg/m2 (800 mg/m2
for patients >65 years of age) twice daily on days 2–8, followed by a 1-week rest, and bevacizumab 5 mg/kg as an
intravenous infusion on day 1 every 2 weeks.
Results: Seventy-seven patients were included in the intention-to-treat and safety populations. Progression-free survival
at 9 months was 61%. The overall response and disease control rates were 51% and 84%, respectively. Median
progression-free and overall survival times were 11.9 and 24.8 months, respectively. 48 patients (62%) had at least one
grade 3/4 adverse event, the most common being asthenia, diarrhoea and neutropenia. Quality of life varied little over
the study period with mean visual analogue scale general health scores ranging from 71 to 76 over cycles 1–11.
Conclusion: Our study found irinotecan and capecitabine administered fortnightly with bevacizumab in patients with
mCRC to be an effective and tolerable regimen.
Trial registration: clinicaltrials.gov identifier NCT00875771. Trial registration date: 04/02/2009.
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According to the World Health Organisation’s most
current statistics there are just over 12.6 million cases of
cancer diagnosed each year. Colorectal cancer is the 5th
most common and accounts for 9.7% of all cancers [1].
Standard treatments for patients with metastatic colo-
rectal cancer (mCRC) usually consist of combination
chemotherapy based on fluorouracil or capecitabine plus
either oxaliplatin or irinotecan, and a targeted agent
such as bevacizumab, cetuximab or panitumumab [2,3].
The most commonly used chemotherapy regimens are* Correspondence: pgarcaalfonso@gmail.com
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article, unless otherwise stated.fluorouracil with folinic acid plus oxaliplatin (FOLFOX),
fluorouracil with folinic acid plus irinotecan (FOLFIRI),
capecitabine plus oxaliplatin (XELOX), and capecitabine
plus irinotecan (XELIRI). However, the optimal sequence
of chemotherapeutic agents is not firmly established,
and most patients will receive a fluoropyrimidine, irino-
tecan and oxaliplatin over the course of their treatment.
Randomised phase III studies have shown that
the addition of bevacizumab to first- or second-line
chemotherapy regimens extends overall survival and/or
progression-free survival in patients with mCRC com-
pared with chemotherapy alone [4-7]. Consequently, beva-
cizumab is indicated for the first- and second-line
treatment of patients with mCRC [2,3].Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tolerable schedule for administering irinotecan-based
regimens such as XELIRI. The BICC-C and EORTC
40015 studies suggested that 3-weekly administration of
irinotecan plus capecitabine can be associated with un-
acceptable gastrointestinal side effects [8,9], although
both studies were confounded by the concomitant use of
celecoxib, which is known to be associated with gastro-
intestinal toxicity. Consequently, different drug doses
and administration regimens have been investigated with
the aim of improving the tolerability of the combination
of irinotecan and capecitabine [10-12].
We have previously shown that 2-weekly irinotecan
plus capecitabine (irinotecan on day 1 every 2 weeks;
plus capecitabine on days 1–7, followed by a week of
rest) was effective and well tolerated in patients with
mCRC [13]. Preclinical studies had shown this 2-weekly
schedule, which is similar to the FOLFIRI schedule, to
be more effective than the standard 3-weekly regimen
and to allow the administration of higher capecitabine
doses [14]. In our study, the adverse-event profile of
XELIRI was acceptable, with asthenia, nausea, vomiting
and diarrhoea being the most commonly observed grade
3/4 adverse events (occurring in 7–9% of patients). Dose
delays and reductions occurred in <12% of patients for
irinotecan and <5% of patients for capecitabine [13]. We
subsequently incorporated bevacizumab into this regi-
men and demonstrated that this combination of a tar-
geted agent with chemotherapy was effective and well
tolerated in patients with mCRC [15].
The present phase II multicentre study was under-
taken on behalf of the Spanish Cooperative Group for
the Treatment of Digestive Tumors (TTD) to assess the
efficacy and tolerability of 2-weekly regimen of irinote-
can in combination with capecitabine plus bevacizumab
in a larger population of previously untreated patients
with mCRC.
Methods
Patients and study design
Patients ≥18 years of age with histologically proven,
measurable mCRC that was not initially totally resected
were included in this phase II open-label study. To be
included, patients had an Eastern Cooperative Oncology
Group (ECOG) performance status of 0–2 and could
have had prior surgical treatment of their disease. No
prior chemotherapy was allowed, other than adjuvant or
neoadjuvant therapy completed at least 6 months before
inclusion in the study; patients who received adjuvant
therapy must not have progressed during or within 6
months of completing treatment. Additionally each pa-
tient was discussed by a multi-disciplinary team within
each cancer centre to confirm their suitability for inclu-
sion in the study.Patients were not eligible for inclusion in the study if
they had a history of central nervous system disease, psy-
chiatric disability, clinically significant cardiac disease, lack
of integrity of the upper gastrointestinal tract, malabsorp-
tion syndrome or inability to take oral medication. Exclu-
sion criteria included any surgical procedures in the 28
days before the start of the study or if any surgery was
scheduled to take place during the study. The use of oral
anticoagulants or full-dose parenteral thrombolytic agents
was not permitted, although low-dose warfarin was
allowed. Chronic treatment with high-dose aspirin or anti-
platelet agents was not permitted.
Patients with creatinine clearance <30 mL/minute or
serum creatinine >1.5 times the upper limit of normal
(ULN) were excluded from the study, as were those
with: an absolute neutrophil count <1.5 × 109/L; platelet
count <100 × 109/L; haemoglobin <9 g/dL; International
Normalised Ratio >1.5; total bilirubin >1.5 × ULN; alanine
aminotransferase and/or aspartate aminotransferase >2.5 x
ULN (or >5 × ULN in case of liver metastases); or alkaline
phosphatase >2.5 × ULN (or >5 × ULN in case of liver
metastases or >10 × ULN in case of bone metastases).
The study protocol (Study TTD-08-03; EudraCT: 2008-
004688-20; clinicaltrials.gov identifier NCT00875771) was
approved by the Spanish Medicine Agency as well as the
Institutional Review Board and Ethics Committee of each
participating site (for details please refer to the Additional
file 1). Reference Ethic Committee: “Comité Ético de
Investigación Clínica” of the Hospital Universitario de
Burgos, Avda. del Cid, 96,09005 Burgos on January 2009.
Study procedures were carried out in accordance with the
Declaration of Helsinki and its subsequent amendments,
and Good Clinical Practice guidelines. Written, informed
consent was obtained from all patients before enrolment.
Treatment
Treatment consisted of irinotecan 175 mg/m2 as an intra-
venous infusion on day 1 every 2 weeks, capecitabine 1000
mg/m2 (800 mg/m2 for patients >65 years of age) twice
daily on days 2–8, followed by a 1-week rest, and bevaci-
zumab 5 mg/kg as an intravenous infusion on day 1 every
2 weeks. Treatment was continued until disease progres-
sion, unacceptable toxicity or patient withdrawal.
The doses of the chemotherapeutic agents were modified
appropriately in each cycle according to the occurrence of
toxicities. Once a dose was reduced, doses were not in-
creased in subsequent cycles. If two dose reductions were
sanctioned as a result of toxicity, patients experiencing the
same complications were withdrawn from the study unless
they had achieved an objective response to treatment, in
which case the decision to continue treatment was left to
the judgment of the investigator. If chemotherapy was de-
layed, administration of bevacizumab was also delayed. If
the administration of chemotherapy was delayed for more
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irinotecan was discontinued, capecitabine and bevacizumab
were to be continued unless unacceptable toxicity was ob-
served. Similarly, if either capecitabine or bevacizumab
were interrupted, treatment with the remaining agents
could be continued at the investigator’s discretion.Assessments
The response to treatment was assessed using the radio-
logical RECIST criteria [16] at 6-cycle intervals until the
disease progressed or the patient died. No independent
radiological review committee was established.
Adverse events were assessed at study visits and re-
ported by patients. Adverse events were classified ac-
cording to the National Cancer Institute Common
Toxicity Criteria (CTC) version 3.0 [17]). All adverse
events, regardless of their relation to the study treat-
ment, were followed until resolution even if patients had
withdrawn from the study.
Quality of life was measured using the EuroQoL 5-
Dimensions (3-level) questionnaire (EQ-5D-3 L), a gen-
eric instrument used for measuring health status [18].
Quality of life assessments were performed at baseline,
before each odd-numbered cycle (3, 5, 7, etc.) and in the
30 days following discontinuation of study therapy. A
minimum of three assessments was required for the pa-
tient’s data to be included in the quality of life analysis.
The EQ-5D-3 L assesses five different aspects of health
(mobility, personal care, daily activities, pain/discomfort
and anxiety/depression), each with three response cat-
egories. In addition, self-assessed general health was re-
corded using a 20 cm visual analogue scale (VAS)
ranging from 0 (“worst imaginable health state”) to 100
(“best imaginable health state”).Statistical analyses
The primary endpoint of this phase II study was
progression-free survival at 9 months. The secondary
endpoints were: progression-free survival, overall sur-
vival, response rate, safety, resection rate and quality of
life. Efficacy analyses were performed on the intention-
to-treat population i.e. patients who received at least one
dose of study medication. Safety analyses were per-
formed on patients who received at least one dose of
study medication (the safety population).
The sample size was based on a single-stage Fleming
design, with p0 = 12% at 2 years (equivalent to a median
progression-free survival of 8 months), p1 = 25%
(equivalent to a median progression-free survival of 12
months), and an alpha error of 0.05 and a beta error of
0.01, resulting in a requirement for seventy-one evalu-
able patients. Allowing for a 10% dropout rate, seventy-
nine patients were planned to be recruited.Survival analyses were performed using Kaplan–Meier
methodology; 95% confidence intervals (CIs) were calcu-
lated for the primary and secondary outcomes. Qualitative
variables were described using absolute and relative fre-
quencies; quantitative variables were described with
means, medians and standard deviation (SD). All analyses
were performed using SPSS version 17.0 (SPSS Inc. Re-
leased 2008. SPSS Statistics for Windows, Version 17.0.
Chicago: SPSS Inc.).Results
Patients
A total of eighty-one patients were enrolled in the study
at twelve Spanish centres between 14 April 2009 and 20
April 2010. Four patients failed the screening process,
with three violating entry criteria; one patient was hospi-
talised prior to initiation of treatment and could not be
treated with the study regimen. The remaining seventy-
seven patients received treatment and were included in
the intention-to-treat and safety populations.
Patient characteristics are summarised in Table 1. A
total of sixty-five patients had relevant comorbidities,
the most common being hypertension in 32 patients
(42%, twenty-seven of whom were taking antihyperten-
sive agents) and 14 patients (18%) with diabetes mellitus.
Twenty-one (27%) patients were ≥70 years of age. Fifty
patients (65%) had undergone surgical resection of the
primary tumour. Of the remaining twenty-seven patients
who did not have surgical resection, four presented with
intestinal perforation or occlusion.
Tumour KRAS status was determined in seventy-one pa-
tients (92%); thirty-six patients (51%) had wild-type KRAS
tumours and thirty-five (49%) had mutant KRAS tumours.Treatment
Patients underwent treatment for a median of 6.2 months
(range 0.4–21.6 months) and received a total of 1009 cy-
cles (876 cycles of bevacizumab, 973 cycles of irinotecan
and 982 cycles of capecitabine). A median of 12.0 cycles
(range 1.0–43.0 cycles) was administered; the median
number of cycles of irinotecan, capecitabine and bevacizu-
mab administered were 12.0 (range 1.0–43.0), 12.0 (range
1.0–43.0) and 11.0 (range 1.0–33.0), respectively.
The median relative dose intensities were: bevacizumab
89%, irinotecan 85%, and capecitabine 89%. Absolute me-
dian dose intensities were: bevacizumab 2.1 mg/kg/week,
irinotecan 77.5 mg/m2/week, capecitabine 1439 mg/day.
Treatment was delayed in fifty-seven patients (74%)
resulting in delays in 160 of the 1009 cycles (16%). The
most common reasons for delayed doses were: neutro-
penia (25 cycles; 16%), administrative reasons (23 cycles;
14%); diarrhoea (19 cycles; 12%) and patient decision
(15 cycles; 9%).




Median age, years (range) 65 (41–81)




Location of primary tumour N %
Rectum 24 31.2
Colon 41 53.2
Colon and rectum 12 15.6




Prior therapy N %
Surgery 50 64.9
Adjuvant chemotherapy 27 35.1
Radiotherapy 9 11.7









Abbreviation: ECOG Eastern Cooperative Oncology Group.
Table 2 Efficacy (N = 77)
Outcome Months 95% CI
Median time to progression 11.9 10.8–13.1
Median progression-free survival 11.8 10.7–13.0
Median overall survival 24.8 19.9–29.7
Response to treatment N %
Complete response 4 5.2
Partial response 35 45.5
Stable disease 26 33.8
Progressive disease 5 6.5
Not evaluable 7 9.1
Response rates % 95% CI
Overall response rate 50.6 39.1–62.0
Disease control rate 84.4 74.0–91.3
Abbreviation: CI confidence interval.
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four patients (31%), most commonly as a result of
thromboembolism (67 cycles; 56%), fistula (9 cycles; 8%),
wound-healing complications (8 cycles; 7%), and surgery
(9 cycles; 8%). The irinotecan dose was reduced or delayed
in 78 cycles (8%) in thirty-seven patients (48%) most com-
monly as a result of asthenia (12 cycles; 15%), diarrhoea
(13 cycles; 17%) and at the discretion of the investigator
(22 cycles; 28%). The capecitabine dose was reduced or
delayed in 85 cycles (9%) in forty-six patients (60%) pri-
marily as a result of diarrhoea (18 cycles; 21%).
Most patients received more than one line of treat-
ment with sixty-two patients (81%) receiving second-
line therapy, twenty-eight of whom had second-line
bevacizumab-containing regimens. Thirty-seven pa-
tients received third-line and later lines of therapy.Efficacy
Patients were followed for a median of 23.3 months
(range 0.4–39.6 months). Efficacy outcomes are shown
in Table 2 and Figure 1. Progression-free survival at 9
months (the primary endpoint) was 61% (95% CI: 48–
73%). The median progression-free survival was 11.9
months (95% CI: 10.8–13.1 months) and median overall
survival was 24.8 months (95% CI: 19.9–29.7 months).
The overall response rate was 51% (95% CI: 39–62%)
and the disease control rate was 84% (95% CI: 74–91%).
Median progression-free survival was 12.0 months
(95% CI: 6.6–17.5 months) in patients with wild-type
KRAS tumours and 11.8 months (95% CI: 10.7–13.0
months) in those with mutant KRAS tumours (P= 0.985)
(Figure 2). Overall survival was also similar in patients
with wild-type and mutant KRAS tumours: 28.5 months
(95% CI: 21.4–35.6 months) versus 27.9 months (95% CI:
21.4–34.3 months), respectively (P= 0.659; Figure 2). Con-
firmed response rates were 44.4% in patients with wild-
type KRAS tumours and 37.1% in those with mutant
KRAS tumours (P >0.05).
Seventeen patients (22%) had surgical resection of me-
tastases during the study (65% liver metastases, 18% lung
metastases, 12% peritoneal metastases and other sites).
The median time to surgery after treatment initiation
was 6.7 months. Twelve patients (71%) underwent R0
resection, three (18%) had an R1 resection and two
(12%) were not evaluable. Thirteen of the seventeen pa-
tients who underwent surgical resection had further
treatment (chemotherapy or immunotherapy). With respect
to second-line chemotherapy six patients received post-
surgical treatment with bevacizumab plus capecitabine/
irinotecan and three patients received other bevacizumab-
containing regimens. The remaining patients received a




Figure 1 Overall survival (A) and progression-free survival (B) in patients treated with bevacizumab, capecitabine and irinotecan every 2 weeks.
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To date, forty-five patients (58%) have died and thirty-two
(42%) are still alive. The causes of death were: progressive
disease (N = 35), adverse events (N = 7) and unknown
(N = 3). Adverse events leading to death included:
multi-organ failure (N = 2), gastrointestinal perforation
(N = 2), respiratory and cardiac insufficiency due to
chronic obstructive pulmonary disease (N = 1), myocar-
dial infarction (N = 1) and respiratory insufficiency (N = 1).
One of the gastrointestinal perforation events was con-
sidered to be related to treatment with bevacizumab;
the two multi-organ failures were considered followingdiscussion and scrutiny by the investigators to be re-
lated to capecitabine/irinotecan, rather than to disease
progression as these events were reported in the con-
text of toxicities.
A total of seventy-six patients (99%) had at least one
adverse event related to treatment; forty-eight patients
(62%) had at least one grade 3 or 4 adverse event. The
most common grade 3 and 4 related adverse events
were asthenia, diarrhoea and neutropenia (Table 3).
Adverse events of special interest for bevacizumab are
summarised in Table 4. Pulmonary embolism occurred
in 10 patients, four of whom were >70 years of age;
A 
B 
            Mutated 
           Wild-type 
            Mutated 
           Wild-type 
Figure 2 Overall survival (A) and progression-free survival (B) according to tumour KRAS status in patients treated with bevacizumab, capecitabine
and irinotecan every 2 weeks.
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symptomatic.
Quality of life
EQ-5D-3 L questionnaires were completed by 70 patients
(91%) at cycle 1, 58 of 70 patients (83%) at cycle 3, 49 of 64
patients (77%) at cycle 5, 38 of 55 patients (69%) at cycle 7,
36 of 47 patients (77%) at cycle 9, and 31 of 45 patients
(69%) at cycle 11. After this point, the number of
patients who completed questionnaires continued todecline, although some patients completed question-
naires until cycle 43.
Patient quality of life did not vary greatly over the
study period (Figure 3). Most patients reported having
no problems with mobility, patient care or activities of
daily living during the first cycles of treatment. More
than 50% of patients experienced pain or discomfort in
the early cycles, although this proportion decreased as
the study progressed. More than half of all patients re-
ported feeling moderately or very anxious, or depressed
Table 3 Grade 3 and 4 adverse events related to
treatment occurring in >2% of patients (N = 77)
Adverse event Grade 3 Grade 4
N % N %
Neutropenia 5 6.5 3 3.9
Febrile neutropenia 3 3.9 2 2.6
Alopecia 3 3.9 0 0
Hand–foot syndrome 4 5.2 0 0
Vomiting 4 5.2 0 0
Nausea 3 3.9 0 0
Diarrhoea 13 16.9 1 1.3
Asthenia 12 15.6 1 1.3
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scores ranged from 71 to 76 over cycles 1–11 (Figure 3).
Discussion
Considerable uncertainty surrounds the most effective
use of irinotecan in combination with capecitabine for
the treatment of patients with mCRC. Some studies have
shown that irinotecan can be associated with significant
gastrointestinal toxicities and, as a result, several doses
and administration regimens have been investigated in
order to maximise efficacy and tolerability.
This study has demonstrated that administering capecit-
abine–irinotecan plus bevacizumab every 2 weeks is a
feasible and tolerable first-line treatment option for pa-
tients with mCRC. Cross-study comparisons, which
should be made with caution, suggest that median
progression-free survival and overall survival in the
present study (11.8 months and 24.8 months, respectively)
are similar to those reported in other phase II studies of
bevacizumab plus XELIRI [19-22] and superior to those in
which XELIRI was administered without bevacizumab
[8,11,12]. This suggests that the efficacy of treatment was
not compromised by the 2-weekly dosing schedule.
The safety profile of capecitabine–irinotecan plus bev-
acizumab administered every 2 weeks was comparable
with reports from other phase II studies. We observedTable 4 Grade 3 -5 adverse events of interest with
bevacizumab (N = 77)
Adverse event Grade 3 Grade 4 Grade 5
N % N % N %
Hypertension 2 2.6 0 0 0 0
Proteinuria 1 1.3 0 0 0 0
Gastrointestinal perforation 1 1.3 1 1.3 1 1.3
Arterial thrombosis 1 1.3 0 0 0 0
Deep vein thrombosis 1 1.3 1 1.3 0 0
Pulmonary thromboembolism 2 2.6 8 10.4 0 0grade 3/4 diarrhoea in 18% of patients, which is similar
to the 10–19% reported by others [19-22]; moreover,
only one patient had grade 4 diarrhoea. Grade 3/4 neu-
tropenia appeared to be somewhat less common than in
other studies, occurring in 10% of patients in our study
compared with 12–18% reported in those other studies.
Thromboembolic events have been reported as a com-
plication of treatment with XELIRI–bevacizumab in the
French FNCCLC ACCORD 13/0503 study, in which
24% of patients in the XELIRI–bevacizumab arm re-
ported a venous thrombosis or pulmonary embolism
[22]. In the present study, thromboembolic events were
observed in 17% of patients, most of which were asymp-
tomatic. Four of the eight grade 4 pulmonary emboli oc-
curred in patients who were >70 years of age, amongst
whom such events have been reported to be more com-
mon [23,24]. Indeed the incidence of thromboembolic
events increased with age in bevacizumab-treated pa-
tients in the BRiTE registry, although the increase was
not statistically significant after adjustment for baseline
ECOG performance status, hypertension, the absence of
anticoagulant therapy at baseline and prior history of
thromboembolic events [25].
Median dose intensities were 89% for bevacizumab,
85% for irinotecan and 89% for capecitabine, suggesting
that the regimen was generally well tolerated. These
findings were within the confidence intervals of other
studies that have reported on tolerability of the combin-
ation [21,22,26].
Response to treatment was not dependent on tumour
KRAS status, as observed in other studies of bevacizu-
mab plus chemotherapy in patients with mCRC
[7,27-29]. As with the prognostic value of KRAS geno-
type study [29], we found that progression-free survival
and overall survival were not extended significantly in
KRAS wild-type genotypes over the mutant form.
When interpreting these findings, it is important to
note that the KRAS analysis was conducted retrospect-
ively in a non-comparative trial.
Quality of life, as measured using the EQ-5D-3 L ques-
tionnaire, was maintained throughout the study, suggest-
ing that treatment did not have a substantial negative
impact on patients’ everyday activities. The evidence
supports the validity of the EQ-5D-3 L tool in measuring
quality of life in cancer patients [30], although the 5-
level classification system, EQ-5D-5 L, has less ceiling
effect and greater discriminative power [31] and we
would consider using this tool in future studies. It is
tricky to compare the VAS scores in Figure 3 with the EQ-
5D-3 L scores. The subjective nature of the VAS scores
gives some insight into the psychological tolerance of the
effect of treatment on patients than the more objective
EQ-5D-3 L. This self-perception of wellbeing improves
over the course of the study. It would be interesting to
Figure 3 Changes in quality of life over the first 11 cycles of treatment as measured by the EuroQoL 5-Dimensions (3-level) questionnaire and
patients’ VAS assessment of general health. Abbreviation: VAS = visual analogue scale.
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deeply in a separate study.
Conclusions
In conclusion, this multicentre phase II study supports
the use of irinotecan and capecitabine administered
every 2 weeks with bevacizumab in patients with mCRC.
The study included patients with multiple comorbidities,
and elderly patients, and therefore indicates that this is
an effective and tolerable regimen.
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